Abbott projected full-year 2026 adjusted EPS of $5.38 to $5.58, including $0.20 of dilution from the Exact Sciences acquisition. The company also guided to 2026 comparable sales growth of 6.5% to 7.5%. The update is mildly supportive but largely reflects forward guidance rather than a current-quarter operating surprise.
Abbott projected full-year 2026 adjusted EPS of $5.38 to $5.58, including $0.20 of dilution from the Exact Sciences acquisition. The company also guided to 2026 comparable sales growth of 6.5% to 7.5%. The update is mildly supportive but largely reflects forward guidance rather than a current-quarter operating surprise.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
neutral
Sentiment Score
0.15
Ticker Sentiment
